Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients

被引:21
|
作者
Valle-Inclan, Jose Espejo [1 ,2 ,3 ]
Stangl, Christina [1 ,2 ,3 ,4 ]
de Jong, Anouk C. [5 ]
van Dessel, Lisanne F. [5 ]
van Roosmalen, Markus J. [2 ,6 ]
Helmijr, Jean C. A. [5 ]
Renkens, Ivo [1 ,2 ]
Janssen, Roel [1 ,2 ,3 ]
de Blank, Sam [1 ,2 ]
de Witte, Chris J. [1 ,2 ,3 ]
Martens, John W. M. [5 ]
Jansen, Maurice P. H. M. [5 ]
Lolkema, Martijn P. [5 ]
Kloosterman, Wigard P. [1 ,2 ,7 ,8 ]
机构
[1] Univ Med Ctr Utrecht, Ctr Mol Med, Dept Genet, Utrecht, Netherlands
[2] Univ Utrecht, Utrecht, Netherlands
[3] Oncode Inst, Utrecht, Netherlands
[4] Netherlands Canc Inst, Div Mol Oncol, Amsterdam, Netherlands
[5] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[6] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[7] Cyclomics, Utrecht, Netherlands
[8] Frame Canc Therapeut, Amsterdam, Netherlands
关键词
Genomics; Liquid biopsies; Nanopore; Cancer; Structural variation; CELL-FREE DNA; COMPREHENSIVE EVALUATION; HUMAN GENOME; REARRANGEMENTS; DISCOVERY; PLATFORM;
D O I
10.1186/s13073-021-00899-7
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Here, we describe a novel approach for rapid discovery of a set of tumor-specific genomic structural variants (SVs), based on a combination of low coverage cancer genome sequencing using Oxford Nanopore with an SV calling and filtering pipeline. We applied the method to tumor samples of high-grade ovarian and prostate cancer patients and validated on average ten somatic SVs per patient with breakpoint-spanning PCR mini-amplicons. These SVs could be quantified in ctDNA samples of patients with metastatic prostate cancer using a digital PCR assay. The results suggest that SV dynamics correlate with and may improve existing treatment-response biomarkers such as PSA.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients
    Jose Espejo Valle-Inclan
    Christina Stangl
    Anouk C. de Jong
    Lisanne F. van Dessel
    Markus J. van Roosmalen
    Jean C. A. Helmijr
    Ivo Renkens
    Roel Janssen
    Sam de Blank
    Chris J. de Witte
    John W. M. Martens
    Maurice P. H. M. Jansen
    Martijn P. Lolkema
    Wigard P. Kloosterman
    Genome Medicine, 13
  • [2] Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer
    Hofste, Lisa S. M.
    Geerlings, Maartje J.
    von Rhein, Daniel
    Tolmeijer, Sofie H.
    Weiss, Marjan M.
    Gilissen, Christian
    Hofste, Tom
    Garms, Linda M.
    Janssen, Marcel J. R.
    Rutten, Heidi
    Rosman, Camiel
    van der Post, Rachel S.
    Klarenbeek, Bastiaan R.
    Ligtenberg, Marjolijn J. L.
    CANCERS, 2022, 14 (18)
  • [3] Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients
    Eroglu, Zeynep
    Krinshpun, Shifra
    Kalashnikova, Ekaterina
    Sudhaman, Sumedha
    Topcu, Turkan Ozturk
    Nichols, Matt
    Martin, Justin
    Bui, Katherine M.
    Palsuledesai, Charuta C.
    Malhotra, Meenakshi
    Olshan, Perry
    Markowitz, Joseph
    Khushalani, Nikhil I.
    Tarhini, Ahmad A.
    Messina, Jane L.
    Aleshin, Alexey
    CANCER, 2023, 129 (11) : 1723 - 1734
  • [4] Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer
    Kallio, Heini M. L.
    Savolainen, Kalle
    Virtanen, Tuomo
    Ryyppo, Lauri
    Selin, Hanna
    Martikainen, Paivi
    Staff, Synnove
    Kivinummi, Kati
    Sipola, Joonatan
    Vuorinen, Juuso
    Nikkola, Jussi
    Nykter, Matti
    Auranen, Annika
    Annala, Matti
    LIFE SCIENCE ALLIANCE, 2024, 7 (06)
  • [5] Circulating tumor DNA-based detection of molecular residual disease as a biomarker for recurrence monitoring predict disease recurrence in patients with ovarian cancer.
    Lv, Tianjiao
    Shi, Xinyi
    Zhao, Dan
    Sun, Jing
    Wang, Bo
    Lu, Kai
    Zou, ShiPing
    Wang, Jing
    Wang, Qiang
    Feng, Weiwei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Circulating tumor DNA-based molecular residual disease detection for the monitoring of high-grade serous ovarian cancer
    Wang, Xipeng
    Ying, Xiang
    Wang, Yizhi
    Zheng, Xiaocui
    Li, Jiarui
    Li, Xing
    Wang, Kai
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A209 - A209
  • [7] Circulating tumor DNA-based molecular residual disease detection for the monitoring of high-grade serous ovarian cancer.
    Ying, Xiang
    Zheng, Xiaocui
    Wang, Yizhi
    Li, Jiarui
    Li, Xing
    Lin, Guomin
    Wang, Kai
    Wang, Xipeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Deep sequencing of circulating tumor DNA for personalized cancer detection and monitoring
    Diehn, Maximilian
    ANNALS OF ONCOLOGY, 2015, 26 : 3 - 3
  • [9] Circulating tumor DNA-based molecular residual disease predicts relapse in patients with resectable gastric cancer
    Xue, Pei
    Shao, Yanfei
    Zhou, Xueliang
    Li, Haiyan
    Wang, Yang
    Wang, Chenyang
    Zhang, Hao
    Li, Bing
    Shi, Shuo
    Du, Haiwei
    Sun, Jing
    CANCER RESEARCH, 2023, 83 (07)
  • [10] Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer
    Kamatham, Saivaishnavi
    Shahjehan, Faisal
    Kasi, Pashtoon Murtaza
    FRONTIERS IN PHARMACOLOGY, 2020, 11